CytomX Therapeutics (CTMX) Fundamental Analysis: Revenue, Earnings & Valuation

5.69 / 10

Netural

Fundamental analysis rates CTMX neutral (5.7/10). Interest coverage is robust (35.1), PB‑ROE favorable (3.36), and Asset‑MV positive, but revenue fell 44.8% YoY, cost of sales is high (64.4%), and current liabilities dominate total liabilities (88.7%).

Analysis Checks(9/10)

Revenue-MV

Value-5.03

Score2/3

Weight21.28%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value-44.82

Score2/3

Weight0.46%

1M Return0.13%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.83%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value88.69

Score1/3

Weight-5.35%

1M Return-1.69%

PB-ROE

Value3.36

Score3/3

Weight42.26%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.06

Score3/3

Weight2.93%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.89%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-44.82

Score2/3

Weight0.19%

1M Return0.05%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.68%

1M Return-1.13%

Asset-MV

Value-0.55

Score2/3

Weight49.62%

1M Return11.12%

Is CTMX fundamentally strong?

CTMX scores 5.69/10 on fundamentals and holds a Fair valuation at present. Backed by its -41.34% ROE, -22.79% net margin, -47.97 P/E ratio, 9.87 P/B ratio, and -139.47% earnings growth, these metrics solidify its Netural investment rating.